{"id":"https://openalex.org/W2981609698","doi":null,"title":"Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials","display_name":"Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials","alternate_titles":[],"publication_year":2019,"publication_date":"2019-08-01","ids":{"openalex":"https://openalex.org/W2981609698","mag":"2981609698","pmid":"https://pubmed.ncbi.nlm.nih.gov/31424712"},"language":"en","primary_location":{"id":"pmid:31424712","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31424712","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of drugs in dermatology : JDD","raw_type":"Clinical Trial, Phase III"},"parent_works":[],"lineage":["https://openalex.org/W2981609698"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039040970","display_name":"Andrew F Alexis","orcid":"https://orcid.org/0000-0002-1351-9165","observed_orcids":["https://orcid.org/0000-0002-1351-9165"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andrew F. Alexis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112774679","display_name":"Marta I. Rendon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marta Rendon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011739266","display_name":"Jonathan I. Silverberg","orcid":"https://orcid.org/0000-0003-3686-7805","observed_orcids":["https://orcid.org/0000-0003-3686-7805"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jonathan I. Silverberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070890272","display_name":"David M. Pariser","orcid":"https://orcid.org/0000-0003-2250-9361","observed_orcids":["https://orcid.org/0000-0003-2250-9361"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"David M. Pariser","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110530687","display_name":"Benjamin Lockshin","orcid":"https://orcid.org/0000-0001-9256-1814","observed_orcids":["https://orcid.org/0000-0001-9256-1814"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Benjamin Lockshin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078821076","display_name":"Christopher E.M. Griffiths","orcid":"https://orcid.org/0000-0001-5371-4427","observed_orcids":["https://orcid.org/0000-0001-5371-4427"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christopher E.M. Griffiths","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019749903","display_name":"Jamie D. Weisman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jamie Weisman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073722593","display_name":"Andreas Wollenberg","orcid":"https://orcid.org/0000-0003-0177-8722","observed_orcids":["https://orcid.org/0000-0003-0177-8722"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andreas Wollenberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100457716","display_name":"Zhen Chen","orcid":"https://orcid.org/0000-0002-8114-107X","observed_orcids":["https://orcid.org/0000-0002-8114-107X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Zhen Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002503854","display_name":"John D. Davis","orcid":"https://orcid.org/0000-0001-6282-1670","observed_orcids":["https://orcid.org/0000-0001-6282-1670"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John D. Davis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Meng Li","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Meng Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054320048","display_name":"Laurent Eckert","orcid":"https://orcid.org/0000-0002-7801-4125","observed_orcids":["https://orcid.org/0000-0002-7801-4125"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Laurent Eckert","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109415560","display_name":"Abhijit S. Gadkari","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Abhijit Gadkari","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060607282","display_name":"Brad S. Shumel","orcid":"https://orcid.org/0000-0002-9285-8164","observed_orcids":["https://orcid.org/0000-0002-9285-8164"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Brad Shumel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012209760","display_name":"Ana Beatris Rossi","orcid":"https://orcid.org/0000-0001-5345-678X","observed_orcids":["https://orcid.org/0000-0001-5345-678X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ana B. Rossi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077395512","display_name":"Neil M.H. Graham","orcid":"https://orcid.org/0000-0002-1236-2311","observed_orcids":["https://orcid.org/0000-0002-1236-2311"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Neil M.H. Graham","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5032594802","display_name":"Marius Ardeleanu","orcid":"https://orcid.org/0000-0002-7712-6862","observed_orcids":["https://orcid.org/0000-0002-7712-6862"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marius Ardeleanu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.7635,"has_fulltext":false,"cited_by_count":57,"citation_normalized_percentile":{"value":0.95009384,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"18","issue":"8","first_page":"804","last_page":"813"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dupilumab","display_name":"dupilumab","score":1.0},{"id":"https://openalex.org/keywords/atopic-dermatitis","display_name":"atopic dermatitis","score":0.9810000061988831},{"id":"https://openalex.org/keywords/racial-subgroups","display_name":"racial subgroups","score":0.8759999871253967},{"id":"https://openalex.org/keywords/il-4-receptor-alpha","display_name":"IL-4 receptor alpha","score":0.6830000281333923},{"id":"https://openalex.org/keywords/il-13-receptor-alpha","display_name":"IL-13 receptor alpha","score":0.9539999961853027},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8330000042915344},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.6930000185966492},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.7179999947547913},{"id":"https://openalex.org/keywords/black-patients","display_name":"Black patients","score":0.7990000247955322},{"id":"https://openalex.org/keywords/asian-patients","display_name":"Asian patients","score":0.6940000057220459},{"id":"https://openalex.org/keywords/pruritus","display_name":"pruritus","score":0.7009999752044678},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.878000020980835},{"id":"https://openalex.org/keywords/eczema-area-and-severity-index","display_name":"Eczema Area and Severity Index","score":0.8700000047683716},{"id":"https://openalex.org/keywords/post-hoc-analysis","display_name":"post hoc analysis","score":0.5249999761581421}],"concepts":[{"id":"https://openalex.org/C2779824493","wikidata":"https://www.wikidata.org/wiki/Q5315925","display_name":"Dupilumab","level":3,"score":0.968169629573822},{"id":"https://openalex.org/C2780699399","wikidata":"https://www.wikidata.org/wiki/Q20708049","display_name":"Eczema Area and Severity Index","level":3,"score":0.9365370273590088},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.890025794506073},{"id":"https://openalex.org/C2778329239","wikidata":"https://www.wikidata.org/wiki/Q268667","display_name":"Atopic dermatitis","level":2,"score":0.8605833649635315},{"id":"https://openalex.org/C2776173921","wikidata":"https://www.wikidata.org/wiki/Q25326609","display_name":"Dermatology Life Quality Index","level":3,"score":0.818328857421875},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7262203097343445},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.6642847061157227},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5394234657287598},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.48888128995895386},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.4881304204463959},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4802870452404022},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41157156229019165},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.36233657598495483},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.19676834344863892},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.18733295798301697},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.09587493538856506},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001741","descriptor_name":"Black or African American","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D003876","descriptor_name":"Dermatitis, Atopic","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D003876","descriptor_name":"Dermatitis, Atopic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010919","descriptor_name":"Placebos","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010919","descriptor_name":"Placebos","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D044465","descriptor_name":"White People","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D044466","descriptor_name":"Asian People","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:31424712","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31424712","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of drugs in dermatology : JDD","raw_type":"Clinical Trial, Phase III"},{"id":"mag:2981609698","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31424712","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7134243887","https://openalex.org/W4362703364","https://openalex.org/W2790635214","https://openalex.org/W4220959337","https://openalex.org/W2174132185","https://openalex.org/W3189569397","https://openalex.org/W4295255262","https://openalex.org/W4238527115","https://openalex.org/W2768316472","https://openalex.org/W4303986849"],"abstract_inverted_index":{"Dupilumab,":[0],"a":[1,263],"monoclonal":[2],"antibody":[3],"that":[4],"blocks":[5],"the":[6,19,53,95,132,156,173,187,193],"shared":[7],"receptor":[8],"subunit":[9],"for":[10,18,36],"interleukin":[11],"(IL)-4":[12],"and":[13,32,55,78,86,101,116,126,161,169,189,204,211,262,278],"IL-13,":[14],"is":[15,41],"currently":[16],"approved":[17],"treatment":[20,167,247,257,272],"of":[21,34,57,135,143,275],"adults":[22],"with":[23,184,215,230,245,270,283,288],"inadequately":[24,286],"controlled":[25,287],"moderate-to-severe":[26,284],"atopic":[27],"dermatitis":[28],"(AD).":[29],"The":[30],"efficacy":[31,54],"safety":[33,56,233],"dupilumab":[35,58,176,198,220,271],"AD":[37,71,285],"among":[38],"racial":[39,62,170,237,281],"subgroups":[40,282],"unknown.":[42],"This":[43],"post":[44],"hoc":[45],"analysis":[46],"from":[47,69,89],"three":[48,174],"phase":[49],"3":[50,138],"trials":[51],"assessed":[52,130,181],"vs":[59,213],"placebo":[60,185],"by":[61,131],"subgroup":[63],"(White,":[64],"Asian,":[65,277],"Black/African":[66,150,195,279],"American).":[67],"Data":[68],"LIBERTY":[70],"SOLO":[72,75],"1":[73],"(NCT02277743),":[74],"2":[76],"(NCT02277769),":[77],"CHRONOS":[79],"(NCT02260986)":[80],"were":[81,153,164,253],"pooled.":[82],"Outcomes":[83],"included":[84,154],"mean":[85,205],"percent":[87],"change":[88],"baseline":[90],"to":[91,250],"week":[92],"16":[93],"in":[94,155,186,207,221,235,255,273],"key":[96],"therapeutic":[97],"domains":[98],"Eczema":[99,118],"Area":[100],"Severity":[102],"Index":[103,114],"(EASI),":[104],"Peak":[105,208],"Pruritus":[106,209],"Numerical":[107],"Rating":[108],"Scale":[109],"(NRS),":[110],"Dermatology":[111],"Life":[112],"Quality":[113,134],"(DLQI),":[115],"Patient-Oriented":[117],"Measure,":[119],"as":[120,122],"well":[121,228],"Investigator\u2019s":[123],"Global":[124],"Assessment":[125],"pain":[127],"or":[128],"discomfort":[129],"European":[133],"Life-5":[136],"Dimensions":[137],"level":[139],"questionnaire.":[140],"A":[141],"total":[142],"2,058":[144],"patients":[145,274],"(White":[146],"n=1,429,":[147],"Asian":[148,190],"n=501,":[149],"American":[151,196,280],"n=128)":[152],"current":[157],"analysis.":[158],"Baseline":[159],"demographics":[160],"disease":[162],"characteristics":[163],"balanced":[165],"between":[166],"groups":[168],"subgroups.":[171,191,238],"In":[172,192],"trials,":[175],"significantly":[177,199],"(P<0.0001)":[178,200],"improved":[179,201],"all":[180,222,236,256],"outcomes":[182],"compared":[183],"White":[188],"smaller":[194],"subgroup,":[197],"EASI":[202],"endpoints":[203],"changes":[206],"NRS":[210],"DLQI":[212],"placebo,":[214],"positive":[216],"numeric":[217],"trends":[218],"favoring":[219],"other":[223],"endpoints.":[224],"Dupilumab":[225],"was":[226],"generally":[227],"tolerated,":[229],"an":[231],"acceptable":[232],"profile":[234,266],"Serious":[239],"adverse":[240,251],"events":[241,252],"occurred":[242],"more":[243],"frequently":[244],"placebo;":[246],"discontinuations":[248],"due":[249],"rare":[254],"groups.":[258],"Significant":[259],"clinical":[260],"improvement":[261],"favorable":[264],"benefit-risk":[265],"can":[267],"be":[268],"achieved":[269],"White,":[276],"topical":[289],"medications.":[290],"ClinicalTrials.gov":[291],"identifiers:":[292],"NCT02277743,":[293],"NCT02277769,":[294],"NCT02260986":[295]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2981609698","counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":15},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":8}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2019-11-01T00:00:00"}
